Background
death, VTE, respiratory syndrome, bleeding
CORONAVIRUS DISEASE 19, BLEEDING, ARTERIAL THROMBOSIS
Governments and health official worldwide are still facing the challenge of the severe respiratory syndrome epidemic due to the Coronavirus Disease 19 (COVID-19) [Studies in ICU patients, such as the INSPIRATION trial, showed no benefit of intermediate doses of LMWH when compared with standard-dose prophylaxis, on the primary outcome (a composite of adjudicated acute VTE, arterial thrombosis, treatment with extracorporeal membrane oxygenation, or death) with more bleeding in the intermediate-dose group [